OTCMKTS:SKVI - Skinvisible Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.27 0.00 (0.00 %) (As of 05/22/2019 12:36 PM ET)Previous Close$0.27Today's Range$0.27 - $0.2752-Week Range$0.10 - $2.00Volume1,000 shsAverage Volume5,849 shsMarket Capitalization$782,190.00P/E RatioN/ADividend YieldN/ABeta1.18 ProfileChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic markets. Its non-dermatological formulations offer solutions for women's health, pain management, and others markets. The company offers sunless tanning, anti-aging, and sunscreen products. Skinvisible, Inc. also licenses its products to manufacturers and marketers of brands internationally, as well as sells directly in the market; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was founded in 1998 and is based in Las Vegas, Nevada. Receive SKVI News and Ratings via Email Sign-up to receive the latest news and ratings for SKVI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SKVI Previous Symbol CUSIPN/A CIK1085277 Webhttp://www.skinvisible.com/ Phone702-433-7154Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$70,000.00 Price / Sales11.17 Cash FlowN/A Price / Cash FlowN/A Book Value($1.63) per share Price / Book-0.17Profitability EPS (Most Recent Fiscal Year)N/A Net Income$160,000.00 Net Margins190.33% Return on Equity-2.76% Return on Assets52.59%Miscellaneous Employees3 Outstanding Shares2,897,000Market Cap$782,190.00 Next Earnings DateN/A OptionableNot Optionable Skinvisible (OTCMKTS:SKVI) Frequently Asked Questions What is Skinvisible's stock symbol? Skinvisible trades on the OTCMKTS under the ticker symbol "SKVI." Has Skinvisible been receiving favorable news coverage? Media headlines about SKVI stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Skinvisible earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of Skinvisible's key competitors? Some companies that are related to Skinvisible include Pernix Therapeutics (PTX), Boston Therapeutics (BTHE), Propanc Biopharma (PPCB), Immune Therapeutics (IMUN), Global Future City (FTCY), ContraVir Pharmaceuticals (CTRV), American Bio Medica (ABMC), RXi Pharmaceuticals (RXII), Cotinga Pharmaceuticals (COTQF), Anthera Pharmaceuticals (ANTH), Capstone Therapeutics (CAPS), HST Global (HSTC), Aoxing Pharmaceutical (AOXG), Argos Therapeutics (ARGSQ) and Affymax (AFFY). What other stocks do shareholders of Skinvisible own? Based on aggregate information from My MarketBeat watchlists, some companies that other Skinvisible investors own include Hexo (HEXO), One Horizon Group (OHGI), Magnegas Applied Tchnlgy Sltns (MNGA), Microbot Medical (MBOT), Jaguar Health (JAGX), HEXO (HEXO), Fred's (FRED), China Recycling Energy (CREG), China Auto Logistics (CALI) and Akari Therapeutics (AKTX). Who are Skinvisible's key executives? Skinvisible's management team includes the folowing people: Mr. Terry H. Howlett, Pres, CEO, CFO & Director (Age 71)Ms. Doreen McMorran, Head/VP of Bus. Devel. & Marketing (Age 56)Dr. Geert Cauwenbergh, Head of International Advisory Board (Age 65) How do I buy shares of Skinvisible? Shares of SKVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Skinvisible's stock price today? One share of SKVI stock can currently be purchased for approximately $0.27. How big of a company is Skinvisible? Skinvisible has a market capitalization of $782,190.00 and generates $70,000.00 in revenue each year. Skinvisible employs 3 workers across the globe. What is Skinvisible's official website? The official website for Skinvisible is http://www.skinvisible.com/. How can I contact Skinvisible? Skinvisible's mailing address is 6320 S SANDHILL ROAD SUITE 10, LAS VEGAS NV, 89120. The company can be reached via phone at 702-433-7154 or via email at [email protected] MarketBeat Community Rating for Skinvisible (OTCMKTS SKVI)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 37 (Vote Outperform)Underperform Votes: 30 (Vote Underperform)Total Votes: 67MarketBeat's community ratings are surveys of what our community members think about Skinvisible and other stocks. Vote "Outperform" if you believe SKVI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SKVI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: How analysts view the yield curve Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.